库尔库和tideglusib仿生纳米系统的有针对性的策略可以缓解缺血性中风下氧化应激和炎症
Jiajia Li1, Yiliang Yang1, Meng Lin1
1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, School of Pharmaceutical Sciences, Peking University, Beijing, PR China.
Drug delivery
|November 26, 2025
概括
血小板膜纳米系统向缺血性大脑输送黄素和提德格卢西布,减少氧化应激和炎症. 这种有针对性的方法增强神经保护,并为缺血性中风治疗提供了一个有希望的策略.
科学领域:
- 神经科学是一个神经科学.
- 生物材料科学 生物材料科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 缺血性中风是全球死亡和残疾的主要原因.
- 需要有效的神经保护策略来对抗氧化应激和炎症.
- 药物输送到缺血性大脑是有限的,阻碍了治疗的有效性.
研究的目的:
- 开发血小板膜 (PLTM) -生物模拟纳米系统,以有针对性地将黄素 (Cur) 和提德格卢西布 (Tid) 输送到缺血性大脑.
- 调查Cur@PLTM和Tid@PLTM在缓解缺血/再生 (I/R) 损伤方面的治疗潜力.
- 探索潜在的机制,包括M2微细胞调节和协同抗氧化和抗炎作用.
主要方法:
- 制造PLTM-生物仿真纳米系统,其中含有黄素和tideglusib.
- 通过卡韦林依赖途径评估活跃向和转细胞化进入缺血大脑.
- 治疗效果的评估,包括反应性氧物种 (ROS) 清除,神经保护性细胞因子分泌和M2微质调节.
- 在体内进行研究,以评估I/R损伤的缓解.
主要成果:
- 库尔@PLTM和Tid@PLTM积极准缺血性大脑,并进行了卡韦林依赖转细胞.
- 这些纳米系统展示了协同作用的ROS清理,并促进了神经保护性细胞因子分泌.
- 治疗效应与M2微质调节有关.
- 联合治疗有效地缓解了缺血/再输液损伤.
结论:
- 血小板膜生物模拟纳米系统为针对性脑药物输送提供了一种新的策略.
- 该Cur@PLTM和Tid@PLTM组合为缺血性中风治疗提供了一种协同的抗氧化和抗炎方法.
- 这种方法有望改善缺血性中风患者的临床结果.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...